Neuropathic Pain Clinical Trial
Official title:
Effect of Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP) in Spinal Cord Injury (SCI) Patients. Preliminary Study.
Hypothesis:
ITB bolus can have antinociceptive effect on neuropathic pain in spinal cord injury patients,
which could depend on the subtype of pain, or on the lesion level, cervical or thoracic
spinal cord injury.
Objective:
To study the effect of intrathecal baclofen bolus on neuropathic pain in patients with spinal
cord injury at cervico-dorsal level.
Primary Endpoint:
Effect of intrathecal baclofen bolus in neuropathic pain (measured using the Neuropathic Pain
Inventory Scale, the Brief Pain Inventory and the Numerical Rating Scale) in spinal cord
injury at cervico-dorsal level.
Secondary Endpoints:
1. Spasticity and spasms (measured using the Modified Ashworth Scale and the Visual
Analogue Scale and Penn Spasm Frequency Scale).
2. Neurophysiological examination (warm perception threshold, heat pain perception
threshold, evoked pain perception and contact heat evoked potentials).
The study will be a randomized, double-blind (patients and who will realize the clinical and
neurophysiologic evaluation), placebo-controlled trial. We will recruit 10-12 patients with
SCI with complete or incomplete lesion at cervical or thoracic level to be randomly
distributed in two study groups: ITB bolus group and a placebo group.
In 6-8 months, we will administer an intrathecal baclofen bolus of 50 µg (1ml) in 5-6 SCI
patients or 1ml of physiologic serum subcutaneously in the other 5-6 SCI patients.
Before the intrathecal baclofen or placebo bolus is administered, patients will be evaluated
for neuropathic pain, using the Neuropathic Pain Inventory Scale, Brief Pain Inventory and
Numerical Rating Scale. Spasticity and spasms will also be measured by the Modified Ashworth
Scale, the Visual Analogue Scale and the Penn Spasm. After that, patients will also undergo,
early in the morning when the intrathecal baclofen or placebo bolus will be administered, a
neurophysiology assessment (warm perception threshold, heat pain perception threshold, evoked
pain perception and contact heat evoked potentials).
After the neurophysiological evaluation, patients will receive an intrathecal baclofen bolus
of 50 µg or placebo (randomization). After the intrathecal baclofen or placebo injection, a
clinical and neurophysiological examination, of neuropathic pain and spasticity and spasms,
will be repeated at 1, 2 and 4 hours after the bolus administration. Moreover, Kumru et al.
(2013) reported that the 50 µg intrathecal baclofen bolus reduced the pain perception
threshold and evoked acute pain perception in patients with SCI.
During all evaluation period, the patients continue with their analgesic, antispastic and/or
any other stable medication.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
| Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
| Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
| Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
| Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
| Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
| Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
| Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
| Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
| Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
| Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
| Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
| Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
| Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
| Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
| Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 | |
| Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 |